Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.

Pharm Res

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, H517 Cooke-Hochstetter, Buffalo, NY 14260, USA.

Published: September 2006

Purpose: To investigate if gamma-Hydroxybutyrate (GHB) tolerance is mediated by alterations in GHB systemic pharmacokinetics, transport (blood brain barrier (BBB) and neuronal) or membrane fluidity.

Materials And Methods: GHB tolerance in rats was attained by repeated GHB administration (5.31 mmol/kg, s.c., QD for 5 days). GHB sedative/hypnotic effects were measured daily. GHB pharmacokinetics were determined on day 5. In separate groups, on day 6, in situ brain perfusion was performed to assess BBB transport alterations; or in vitro studies were performed (fluorescence polarization measurements of neuronal membrane fluidity or [3H]GABA neuronal accumulation).

Results: GHB sedative/hypnotic tolerance was observed by day 5. No significant GHB pharmacokinetic or BBB transport differences were observed between treated and control rats. Neuronal membrane preparations from GHB tolerant rats showed a significant decrease in fluorescence polarization (treated-0.320 +/- 0.009, n = 5; control-0.299 +/- 0.009, n = 5; p < 0.05). [3H]GABA neuronal transport Vmax was significantly increased in tolerant rats (2,110.66 +/- 91.06 pmol/mg protein/min vs control (1,612.68 +/- 176.03 pmol/mg protein/min; n = 7 p < 0.05).

Conclusions: Short term GHB administration at moderate doses results in the development of tolerance which is not due to altered systemic pharmacokinetics or altered BBB transport, but might be due to enhanced membrane rigidity and increased GABA reuptake.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-006-9066-6DOI Listing

Publication Analysis

Top Keywords

ghb sedative/hypnotic
12
neuronal membrane
12
bbb transport
12
ghb
11
neuronal transport
8
gamma-hydroxybutyrate ghb
8
sedative/hypnotic tolerance
8
ghb tolerance
8
systemic pharmacokinetics
8
ghb administration
8

Similar Publications

Dose titration of intravenously administered gamma-hydroxybutyric acid for sedation in Holstein-Friesian calves.

Vet J

December 2024

Department of Large Animal Surgery, Anaesthesia and Orthopaedics, Ghent University, Merelbeke 9820, Belgium.

Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid that can potentially provide safe, prolonged sedation with minimal cardiorespiratory effects. This preliminary trial, performed in 10 three-week-old male Holstein-Friesian calves, investigated the effects of GHB administered intravenously over 5 min at a dose of 100 (G100, n=2), 150 (G150, n=4) or 200 mg/kg (G200, n=4). Once lateral recumbency was achieved, scores for sedation depth (range: 0 = no sedation to 3 = marked) and response to noxious stimulation (range: 0 = strong to 3 = absent), heart rate (HR), respiratory rate (RR), mean arterial pressure (MAP) and arterial blood gases were monitored every 15 min until sternal recumbency.

View Article and Find Full Text PDF

Treatment of Gamma Hydroxybutyrate Withdrawal in a Pregnant Female: A Case Report.

J Addict Med

June 2024

From the Simon Fraser University, Vancouver, Canada (SJ); FISAM Family and Addiction Medicine Physician, Perinatal Addiction Medical Lead, Island Health, Victoria, Canada (SL); BCCSU Addiction Medicine Fellowship, Island Health, Vancouver Island, Canada (MW); HerWay Home, Victoria, Canada (MW); and Research and Knowledge Translation in Long-Term Care, Island Health, Vancouver Island, Canada (AL).

Article Synopsis
  • Gamma hydroxybutyrate (GHB) is commonly misused for its sedative effects, posing a risk for substance use disorder and severe withdrawal symptoms, especially in pregnant women, where guidelines for management are lacking.
  • A case involving a 32-year-old pregnant woman showed that using a combination of baclofen and diazepam effectively managed her GHB withdrawal during a 14-day hospital stay, leading to positive outcomes.
  • This case emphasizes the need for more research and guidelines on GHB withdrawal treatment in pregnancy, as it provides insight into effective management that could assist healthcare providers in the future.
View Article and Find Full Text PDF

Sex and Cross-Sex Testosterone Treatment Alters Gamma-Hydroxybutyrate Acid Toxicokinetics and Toxicodynamics in Rats.

Pharmaceutics

January 2024

Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA.

Article Synopsis
  • GHB (Γ-hydroxybutyric acid) is a substance known for its sedative effects and is increasingly used recreationally, especially within the LGBTQ+ community.
  • This study examined how administering testosterone impacts the way GHB is processed and its effects on the body, using rats to explore potential treatment strategies for overdose.
  • Results showed that testosterone alters GHB's clearance and sedative effects, suggesting that using a specific inhibitor (MCT1) could improve treatment outcomes for GHB overdose in both cisgender and transgender males.
View Article and Find Full Text PDF

GHB toxicokinetics and renal monocarboxylate transporter expression are influenced by the estrus cycle in rats.

BMC Pharmacol Toxicol

November 2023

Department of Pharmaceutics and Medicinal Chemistry, Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, 95211, USA.

Article Synopsis
  • The study examines the effects of sex hormones and the estrus cycle on the renal clearance of gamma-hydroxybutyric acid (GHB) in female rats compared to males, highlighting an absence of treatments for GHB overdose.
  • Researchers evaluated the toxicokinetics of GHB and the expression of MCT1, SMCT1, and CD147 transporters through blood and urine sampling in different configurations of male and female rats during varied hormonal states.
  • Findings indicate that female rats, particularly in the proestrus phase, show increased renal clearance of GHB and lower transporter expression, suggesting they may be less vulnerable to GHB toxicity than males.
View Article and Find Full Text PDF

Background: Gamma-hydroxybutyric acid (GHB) at low dosages has anxiolytic effects and promotes REM sleep and low-wave deep sleep. In the U.S.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!